San Diego-based Onchilles Pharma said this morning that it has raised $7M in a Series A funding round. The funding came from LYZZ Capital, and also included $500K from the University of Chicago's Startup Investment Fund. According to the company, it is working on an anti-cancer protein released by human neutrophils that activates cell death pathways specifically in cancer cells. The company said the funding will go to advance its first drug candidate through preclinical proo-of-concept. Court R. Turner is cofounder and Executive Chairperson of Onchilles Pharma and Partner at LYZZ Capital.